Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Dec 11;15(12):e50346.
doi: 10.7759/cureus.50346. eCollection 2023 Dec.

No Increase in Acute or Late Radiation Toxicities in Patients With Ehlers-Danlos Syndrome Receiving Adjuvant Breast Radiation Therapy: A Report of Four Cases With Extended Follow-Up

Affiliations
Case Reports

No Increase in Acute or Late Radiation Toxicities in Patients With Ehlers-Danlos Syndrome Receiving Adjuvant Breast Radiation Therapy: A Report of Four Cases With Extended Follow-Up

Michael T Hsieh et al. Cureus. .

Abstract

Ehlers-Danlos syndrome (EDS) consists of a heterogeneous group of congenital collagen formation disorders characterised by skin hyperextensibility, atrophic scarring, and generalized joint hypermobility. Collagen vascular disorders have been implicated in increased incidence and severity of radiation toxicities; however, there are limited reports on the safety of radiation therapy with EDS. We identified all patients with EDS who received adjuvant conventional and hypofractionated breast radiation therapy at our institution and reviewed patient, treatment, and toxicity characteristics. Four patients were identified with a median follow-up of 13.2 months. Acute toxicities were limited to grade 1 dermatitis in all four patients. No late toxicities were seen. In this report, radiation therapy to the breast with conventional and hypofractionated regimens resulted in no significant acute or late toxicity.

Keywords: breast cancer radiation; ehlers-danlos syndrome hypermobility type (eds-ht); ehlers-danlos syndromes; intensity modulated radiation therapy (imrt); radiation oncology complication; radiation therapy side effects; radiotherapy (rt); radiotherapy toxicity.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Similar articles

Cited by

References

    1. The 2017 international classification of the Ehlers-Danlos syndromes. Malfait F, Francomano C, Byers P, et al. Am J Med Genet C Semin Med Genet. 2017;175:8–26. - PubMed
    1. Characteristics, diagnosis, and management of Ehlers-Danlos syndromes: a review. Joseph AW, Joseph SS, Francomano CA, Kontis TC. JAMA Facial Plast Surg. 2018;20:70–75. - PubMed
    1. Toxicity after radiotherapy in patients with historically accepted contraindications to treatment (CONTRAD): an international systematic review and meta-analysis. Lin D, Lehrer EJ, Rosenberg J, Trifiletti DM, Zaorsky NG. Radiother Oncol. 2019;135:147–152. - PubMed
    1. Mediastinal epithelioid hemangioendothelioma in a patient with type IV Ehlers-Danlos syndrome: a case report and review of the literature. Begbie SD, Bell DR, Nevell DF. Am J Clin Oncol. 1997;20:412–415. - PubMed
    1. Successful case of breast conservation radiotherapy in a patient with type III Ehlers-Danlos syndrome. Chau T, Chen AY. Breast J. 2018;24:221–222. - PubMed

Publication types

LinkOut - more resources